Mayo Clinic (Jacksonville)

Sorting 11 by

Accepting patients

RALLY-MF

RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
  • Monoclonal Antibody
  • Hemojuvelin (HJV)
  • Monotherapy
  • Randomization
  • Phase 1/2
  • Has results

Accepting patients

AG-946

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
  • Pyruvate Kinase
  • Phase 2
  • Has results

Accepting patients

OPTIMIZE

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
  • CLK Inhibitor
  • Phase 1/2

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Not yet accepting

CYCLE-1

Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle
  • CAR T Cell
  • Phase 1

Accepting patients

Bone Marrow Failure Clinic Study

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
  • Observational Trial

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

Cord Blood Units for Neutrophil Recovery

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
  • Cord Blood
  • Observational Trial

Not yet accepting

SENTI-202

SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Hematological Malignancies
  • Natural Killer Cells (Allogeneic)
  • CD33
  • FLT3 Inhibitor
  • Phase 1